---
$id: https://graph.org.ai/products/commodity/51111623
$type: Product
source: UNSPSC
code: "51111623"
title: "Amonafide"
class: "51111600"
classTitle: "Antimetabolites"
family: "51110000"
familyTitle: "Antineoplastic agents"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Amonafide

**UNSPSC Code**: 51111623
**Class**: [Antimetabolites](Antimetabolites.mdx)
**Family**: [Antineoplastic agents](../Antineoplastic agents.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes a topoisomerase-ii inhibitor and intercalating agent with the molecular formula C16H17N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1Q8D39N37L, chemically known as 3-amino-n-(2-(dimethylamino)ethyl)-1,8-naphthalindicarboximid but generally known as amonafide, which bears US NIH Compound Identifier 50515. Amonafide most often comes in base and dihydrochloride forms. European Medicines Agency schedules Amonafide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05473MIG. The term AMONAFIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). AMONAFIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amonafide under HS 29251995 and SITC 51482. As of Q4 2014, AMONAFIDE remains the US FDA Preferred Term for this commodity. Amonafide bears US NLM identifiers UMLS ID C0126606 and NCI Concept Code C71628. SMILES: O=C1N(CCN(C)C)C(=O)C2C3C1CC(N)CC3CCC2.

